4523 (4523) News
Follow 4523 (4523) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
By Colin KellaherMerck and Eisai have won U.S. Food and Drug Administration approval of the dual oral regimen of Merck's Welireg plus both companies' Lenvima in certain patients with the most common type of kidney cancer
REGULATION | Sep 25, 2026, 11:05 AM UTC
L
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in
REGULATION | Sep 25, 2026, 10:47 AM UTC
L
FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
FDA
REGULATION | Sep 24, 2026, 07:21 PM UTC
M
Eisai gets Japan approval for weekly LEQEMBI Pen
Eisai received Japanese approval for the LEQEMBI Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, adding an at-home option alongside IV dosing. Eisai leads development with Biogen; studies cited
REGULATION | Sep 18, 2026, 03:44 PM UTC
M
LEQEMBI Pen approved in Japan for early Alzheimer’s
Eisai and Biogen said Japan approved LEQEMBI Pen, the subcutaneous formulation of lecanemab, for early Alzheimer’s disease treatment.
REGULATION | Sep 18, 2026, 03:44 PM UTC
M
Eisai and Biogen announce Japan approval of LEQEMBI Pen
Eisai and Biogen said Japan approved “LEQEMBI Pen,” a subcutaneous formulation for early Alzheimer’s disease.
REGULATION | Sep 16, 2026, 06:01 AM UTC
L
Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
TOKYO, Sept 15, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has entered into an agreement (the "Agreement") with Osaka Prefecture (Governor: Hirofumi Y
NEWS | Sep 15, 2026, 02:03 PM UTC
M
China NMPA approves subcutaneous lecanemab for early Alzheimer’s
Eisai and Biogen said China’s NMPA approved a lecanemab subcutaneous formulation for initiation treatment in early Alzheimer’s, using a subcutaneous autoinjector (SC-AI).
GEOPOLITICS | Sep 08, 2026, 07:47 PM UTC
M
Eisai’s Leqembi subcutaneous initiation treatment approved in China
Eisai Co., Ltd. says its Leqembi (Lecanemab) subcutaneous formulation for initiation treatment in early Alzheimer’s disease has been approved in China.
GEOPOLITICS | Sep 03, 2026, 04:01 AM UTC
L
Leqembi Iqlik autoinjector available in U.S. for early Alzheimer’s
Leqembi Iqlik autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer’s disease.
EQUITY | Aug 27, 2026, 06:58 PM UTC